多发性骨髓瘤及相关疾病的实验室诊断认识

doi:10.16150/j.1671-2870.2017.05.006

摘要/Abstract

中图分类号:

R730.34

汪萍, 沈立松, 张冬青. 多发性骨髓瘤及相关疾病的实验室诊断认识[J]. 诊断学理论与实践, 2017, 16(05): 477-483.

[1] Landgren O, Kyle RA, Pfeiffer RM, et al.Monoclonal gammopathy of undetermined significance(MGUS) consistently precedes multiple myeloma: a prospective study[J]. Blood,2009,113(22):5412-5417.
[2] Weiss BM, Abadie J, Verma P, et al.A monoclonal gammopathy precedes multiple myeloma in most patients[J]. Blood,2009,113(22):5418-5422.
[3] Kyle RA, Durie BG, Rajkumar SV, et al.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management[J]. Leukemia,2010,24(6):1121-1127.
[4] Dispenzieri A, Kyle R, Merlini G, et al.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders[J]. Leukemia,2009,23(2):215-224.
[5] Fonseca R, Bergsagel PL, Drach J, et al.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review[J]. Leukemia,2009, 23(12):2210-2221.
[6] Harousseau JL, Dreyling M, ESMO Guidelines Working Group. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up[J]. Ann Oncol,2009,20(Suppl 4):97-99.
[7] Landgren O.Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology[J]. Hematology Am Soc Hematol Educ Program,2010,2010:295-302.
[8] Katzmann JA.Screening panels for monoclonal gammopathies: time to change[J]. Clin Biochem Rev,2009, 30(3):105-111.
[9] Kristinsson SY, Björkholm M, Andersson TM, et al.Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study[J]. Haematologica,2009, 94(12):1714-1720.
[10] Katzmann JA, Kyle RA, Benson J, et al.Screening pane-ls for detection of monoclonal gammopathies[J]. Clin Chem,2009,55(8):1517-1522.
[11] Kyle RA, Rajkumar SV.Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma[J]. Leukemia,2009,23(1):3-9.
[12] Durie BG, Salmon SE.A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival[J]. Cancer, 1975, 36(3): 842-854.
[13] Landgren O, Gridley G, Turesson I, et al.Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States[J]. Blood,2006,107(3):904-906.
[14] Iwanaga M, Tagawa M, Tsukasaki K, et al.Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan[J]. Mayo Clin Proc,2007,82(12):1474-1479.
[15] Kyle RA, Rajkumar SV.Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma(SMM)[J]. Oncology (Williston Park),2011,25(7):578-586.
[16] Hillengass J, Moehler T, Hundemer M.Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management[J]. Recent Results Cancer Res,2011,183:113-131.
[17] Pérez-Persona E, Vidriales MB, Mateo G, et al.New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells[J]. Blood,2007,110(7):2586-2592.
[18] Kyle RA, Durie BG, Rajkumar SV, et al.Monoclonal gammopathy of undetermined significance(MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management[J]. Leukemia,2010,24(6):1121-1127.
[19] Kyle RA, Remstein ED, Therneau TM, et al.Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma[J]. N Engl J Med,2007,356(25):2582-2590.
[20] Greipp PR, San Miguel J, Durie BG, et al.International staging system for multiple myeloma[J]. J Clin Oncol,2005,23(15):3412-3420.
[21] Fonseca R, Bergsagel PL, Drach J, et al.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review[J]. Leukemia,2009, 23(12):2210-2221.
[22] Bradwell AR, Carr-Smith HD, Mead GP, et al.Serum test for assessment of patients with Bence Jones myeloma[J]. Lancet,2003,361(9356):489-491.
[23] Dingli D, Kyle RA, Rajkumar SV, et al.Immunoglobulin free light chains and solitary plasmacytoma of bone[J]. Blood,2006,108(6):1979-1983.
[24] Durie BG, Harousseau JL, Miguel JS, et al.International uniform response criteria for multiple myeloma[J]. Leukemia,2006,20(9):1467-1473.
[25] Palumbo A, Avet-Loiseau H, Oliva S, et al.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group[J]. J Clin Oncol,2015,33(26):2863-2869.
[26] Fonseca R, Bergsagel PL, Drach J, et al.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review[J]. Leukemia,2009, 23(12):2210-2221.
[27] Keats JJ, Reiman T, Maxwell CA, et al.In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression[J]. Blood,2003,101(4):1520-1529.
[28] Merz M, Hielscher T, Seckinger A, et al.Baseline characteristics, chromosomal alterations, and treatment affec-ting prognosis of deletion 17p in newly diagnosed myeloma[J]. Am J Hematol,2016,91(11):E473-E477.
[29] Fonseca R, Monge J, Dimopoulos MA.Staging and prognostication of multiple myeloma[J]. Expert Rev Hematol,2014,7(1):21-31.
[30] Chng WJ, Price-Troska T, Gonzalez-Paz N, et al.Clinical significance of TP53 mutation in myeloma[J]. Leukemia,2007,21(3):582-584.
[31] Stewart AK, Bergsagel PL, Greipp PR, et al.A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy[J]. Leukemia,2007,21(3):529-534.
[32] Weinhold N, Kirn D, Seckinger A, et al.Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma[J]. Haematologica,2016,101(3):e116-e119.
[33] Palumbo A, Bringhen S, Mateos MV, et al.Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report[J]. Blood,2015,125(13):2068-2074.
[34] Dispenzieri A, Rajkumar SV, Gertz MA, et al.Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement[J]. Mayo Clin Proc,2007, 82(3):323-341.
[35] Kumar SK, Mikhael JR, Buadi FK, et al.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines[J]. Mayo Clin Proc,2009,84(12):1095-1110.
[36] Ria R, Roccaro AM, Merchionne F, et al.Vascular endothelial growth factor and its receptors in multiple myeloma[J]. Leukemia,2003,17(10):1961-1966.
[37] Moreau P, Attal M, Garban F, et al.Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials[J]. Leukemia,2007,21(9):2020-2024.
[38] Fonseca R, Bergsagel PL, Drach J, et al.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review[J]. Leukemia,2009, 23(12):2210-2221.
[39] Zhou Y, Barlogie B, Shaughnessy JD Jr.The molecular characterization and clinical management of multiple myeloma in the post-genome era[J]. Leukemia,2009,23(11):1941-1956.
[40] Decaux O, Lodé L, Magrangeas F, et al.Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome[J]. J Clin Oncol,2008,26(29):4798-4805.
[41] Shaughnessy JD Jr, Zhan F, Burington BE, et al.A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1[J]. Blood,2007,109(6):2276-2284.
[42] Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma[J]. Leukemia,2012,26(11):2406-2413.
[43] Sun RX, Lu ZY, Wijdenes J, et al.Large scale and clinical grade purification of syndecan-1+ malignant plasma cells[J]. J Immunol Methods,1997,205(1):73-79.
[44] Rawstron AC, Orfao A, Beksac M, el al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders[J]. Haematologica,2008,93(3):431-438.
[45] Flanders A, Stetler-Stevenson M, Landgren O.Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity[J]. Blood,2013,122(6):1088-1089.

多发性骨髓瘤及相关疾病的实验室诊断认识

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528.
[2]	寇明坤, 徐娜娜, 石静云, 吴涛. 达妥木单抗在多发性骨髓瘤一线治疗中的应用进展[J]. 诊断学理论与实践, 2021, 20(06): 588-591.
[3]	赵建治, 糜坚青. 多发性骨髓瘤相关生物标志物的研究进展[J]. 诊断学理论与实践, 2021, 20(05): 507-511.
[4]	范春丽, 吴涛, 薛锋, 胡文雪, 王存邦, 白海. MUM1/IRF4阳性弥漫大B细胞淋巴瘤一例治疗报告并文献复习[J]. 诊断学理论与实践, 2021, 20(04): 399-400.
[5]	彭真萍, 项喜喜, 张苏江, 李佳明. 以类白血病反应为首发表现的慢性中性粒细胞白血病二例并文献复习[J]. 诊断学理论与实践, 2020, 19(02): 122-128.
[6]	陆弘逾, 曹亚峰, 顾俊, 王静, 陈梅, 宋陆茜. 神经电生理检查对多发性骨髓瘤患者硼替佐米治疗相关周围神经病的预测及诊断意义[J]. 诊断学理论与实践, 2019, 18(06): 640-644.
[7]	李晓帆, 王少元. 多发性骨髓瘤微小残留病检测及其临床应用[J]. 诊断学理论与实践, 2017, 16(05): 472-476.
[8]	糜坚青, 金诗炜. 多发性骨髓瘤细胞分子遗传学异常与预后分层、治疗[J]. 诊断学理论与实践, 2017, 16(05): 460-463.
[9]	曹亚峰, 王静, 顾俊, 陆弘逾, 许杰, 刘元坊, 王焰, 王瑾, 陈钰, 陈玉宝, 李佳明, 郝杰, 糜坚青, 陈梅. 以硼替佐米为基础的联合方案治疗114例初诊多发性骨髓瘤患者的周围神经病变分析[J]. 诊断学理论与实践, 2017, 16(05): 492-497.
[10]	侯健, 刘进. 2017年欧洲肿瘤内科学会多发性骨髓瘤的指南更新解读[J]. 诊断学理论与实践, 2017, 16(05): 455-459.
[11]	王敏敏, 颜敏超, 郭晓珺. 硼替佐米和沙利度胺治疗多发性骨髓瘤致相关周围神经病变机制[J]. 诊断学理论与实践, 2016, 15(06): 629-631.
[12]	刘占云, 王艳煜, 俞娇, 陈秋生, 李军民, 赵维莅,. 可溶性CD40在部分B细胞淋巴血液肿瘤患者中的表达及临床意义[J]. 诊断学理论与实践, 2012, 11(06): 620-623.
[13]	张曦, 常春康, 吴凌云, 周立宇, 苏基滢, 李晓,. 多发性骨髓瘤患者白蛋白校正后高血钙发生率的研究[J]. 诊断学理论与实践, 2010, 9(03): 233-235.
[14]	黄琴, 张晓燕, 王晓敏,. 多发性骨髓瘤患者血清IL-6的测定及其临床意义[J]. 诊断学理论与实践, 2010, 9(03): 264-265.
[15]	李雪华, 张曦, 常春康, 李晓, 浦权,. 205例多发性骨髓瘤患者骨髓涂片与活检切片内浆细胞浸润的比较研究[J]. 诊断学理论与实践, 2010, 9(01): 63-65.